The ACTIONED Consortium: integrAted moleCular soluTIons fOr diagNostics and Early Detection

采取措施（用于诊断和早期检测的集成分子解决方案），由三个主要合作伙伴组成：1.国家领先的基因组学/基于组织的癌症诊断专家（贝尔法斯特女王大学精准医学卓越中心或PMC）2.全球领先的癌症基因组学和组织诊断诊断解决方案提供商（罗氏）3.在人工智能工具和相关分析框架方面取得早期成功的英国中小企业（Sonrai Analytics）这些合作伙伴之前已经合作过，提供NHS诊断实验室常规使用的产品。这一雄心勃勃的合作伙伴关系的目的是建立，在PMC最先进的认证实验室中，所有与基因组学和基于组织的癌症诊断相关的技术和软件：a）基因组学，通过一种被称为下一代测序的技术，是目前癌症患者个性化医疗的主要驱动力。B）数字病理学和人工智能正在改变我们实践传统病理学的方式，提供迄今为止未知的客观程度和质量控制。一旦建立，三方将致力于这两种途径之间必要的整合，ACTIONED将以结直肠癌为例提供整合，这是一个适用于所有其他癌症类型的模型，解决了两种关键的未满足需求的情况。首先，准确检测II期和III期结直肠癌患者的早期复发，确定那些真正受益于治疗的患者和那些可以避免治疗毒性的患者。第二，真正的早期结直肠癌的检测，作为一个原则的证明。ACTIONED将推动我们的经济增长。事实上，ACTIONED将以北方爱尔兰为中心，提供供整个NHS采用的分析/临床产品。这将提升我们在全球范围内发展医疗保健知识和专业知识整合方面的领导地位。具体而言：a）Sonrai Analytics将发展成为一个具有巨大效益的市场地位b）PMC将成为全球癌症研究的强大参考实验室c）罗氏将为其产品提供更好的价值最后，ACTIONED将通过目前在贝尔法斯特女王大学非常成功的理学硕士课程提供世界领先的教育。罗氏的技术和样品承诺2. Sonrai改善罗氏平台之间的连接和整合的能力3，PMC完全整合和认可的实验室框架以及强大的分子诊断知识，ACTIONED将展示这种整合在我们的NHS中的影响，并改善我们癌症患者的生活。

ACTIONED (integrAted moleCular soluTIons fOr diagNostics and Early Detection) in a consortium of three main partners:1.National leading experts in genomics/tissue-based cancer diagnostics (The Precision Medicine Centre of Excellence at Queen's University Belfast or PMC)2.The leading global provider of diagnostic solutions in cancer genomics and tissue diagnostics (Roche)3.A UK SME with early success in artificial intelligence tools and related analytical frameworks (Sonrai Analytics)These partners have already worked together before, delivering products that routinely used in diagnostic laboratories in the NHS.The purpose of this ambitious partnership is to establish, in PMC's state-of-the-art accredited laboratory, all technology and software relating to genomics and tissue-based cancer diagnostics:a)Genomics, through a technology called Next Generation Sequencing, is the current main driver of personalised medicine to cancer patients.b)Digital Pathology and Artificial Intelligence is transforming the way we practice traditional pathology, delivering a degree of objectivity and quality-control unknown to date.Once established, the 3 parties will work on the integration necessary between these two pathways, impacting testing quality/affordability and clinical decision-making.ACTIONED will provide integration using colorectal cancer as an exemplar, a model to be applicable to all other cancer types, addressing two scenarios of critical unmet need. Firstly, accurate detection of early recurrence in stage II and III colorectal cancer patients, identifying those who will truly benefit from therapy from those who can be spared therapeutic toxicity. Secondly, detection of true early colorectal cancer, addressed as a proof-of-principle.ACTIONED will drive growth in our economy. Indeed, ACTIONED will be centered in Northern Ireland, providing an analytical/clinical product to be adopted by the NHS as a whole. This will enhance our position as leaders in development of healthcare knowledge and know-how integration at a global scale. Specifically:a) Sonrai Analytics will develop into a market position of great benefitb) PMC will become a strong reference laboratory for cancer studies globally.c) Roche will have a better value for its product.Finally, ACTIONED will deliver world-leading education through a very successful MSc currently run in Queen's University Belfast.Strategically, the PMC-Roche-Sonrai partnership within ACTIONED is an unprecedented coalition;1. Roche's technological and sample commitment2. Sonrai's capability to improve connectivity and integration between Roche platforms3, PMC's fully integrated and accredited laboratory framework and strong molecular diagnostic know-howTogether, ACTIONED will show the impact of this integration in our NHS, and improve the lives of our cancer patients.